The FDA recently expanded the indication for the SGLT2 inhibitor empagliflozin to reduce the risk for cardiovascular death and heart failure hospitalization in adults with heart failure with reduced or preserved ejection fraction.
Empagliflozin (Jardiance, Boehringer Ingelheim) was originally approved in 2014 to improve glucose response for adults with type 2 diabetes. The FDA’s announcement of the latest approval was the top story in cardiology last week.
Another top story covered data suggesting that a vegetable-rich diet may not be independently associated with a reduced risk for CVD,